Mayuko Saito, Kentaro Yamashita, Yoshiaki Arimura, Hiroyuki Kaneto, Hiroyuki Okuda, Masanori Nojima, Takeshi Hagiwara, Kazuya Suzuki, Takeya Adachi, Akira Goto, Kohei Nakachi, Atsushi Yawata, Mitsuru Yoshimoto, Tokuma Tanuma, Yasushi Adachi, Satoshi Yamaoka, Tsunenori Mizukoshi, Mariko Kawayama, Yasuo Hamamoto, Yasuhisa Shinomura
BACKGROUND: Intratumoral human epidermal growth factor receptor 2 (HER2) heterogeneity of gastric cancer can be an obstacle to accurate HER2 assessment. Serum HER2, concentrations of the HER2 extracellular domain shed into the bloodstream, has a potential to compensate HER2 immunohistochemistry (IHC) but has not been scrutinized in gastric cancer. This study sought to explore the clinical utility of serum HER2 in gastric cancer. METHODS: We performed a prospective multicenter trial (SHERLOCK trial) involving patients with all-stage gastric or gastro-esophageal junction cancer...
2016: Acta Oncologica